



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Simantov, et al.

Examiner: Davis, N.

Serial No.: 09/730,379

Group Art Unit: 1642

Filed: December 5, 2000

Confirmation No: 7403

Attorney's Docket: 955-7P CON

For: THROMBOSPONDIN-BINDING
REGION OF HISTIDINE-RICH
GLYCOPROTEIN AND
METHODS OF USE

Dated: November 15, 2002

*I hereby certify this correspondence is being sent by
First Class Mail, postage prepaid and addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231 on November 15, 2002*
Signature: *[Signature]*

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

This amendment is submitted in response to the first Office Action in the present case, issued July 16, 2002.

IN THE SPECIFICATION

Please delete the SEQUENCE LISTING at the end of the specification and in its place add the attached new SEQUENCE LISTING of SEQ ID NOS:1-18.

Also please replace informal Figs. 1-3 with formal Figs. 1-3 appended hereto.

On Page 3, please amend the first paragraph beginning with "Although TSP" to read as follows:

Although TSP-1 interacts with a number of distinct cellular receptors, CD36 has been recognized as the critical anti-angiogenesis receptor for TSP-1 (12, 13). The binding of TSP-1 to CD36 is mediated by the peptide sequence cysteine-serine-valine-threonine-cysteine-

RECEIVED
NOV 22 2002
TECH CENTER 1600/2307

2210
140
1-1683

advisory (1-1683)

D1